

C 2
Cont.

7. (twice amended) The method according to claim 5 further comprising determining the ability of the tested substance to induce apoptosis.

9. (twice amended) The method according to claim 5, wherein the glycoprotein is in an isolated form.

10. (twice amended) The method according to claim 5 for identifying a substance that binds specifically to a tumor cell.

11. (amended) The method according to claim 10 for identifying an agent for tumor diagnosis and/or tumor therapy.

C 3

12. (twice amended) The method according to claim 5, wherein the substance tested is pharmaceutically acceptable.

C

13. (amended) The method according to claim 12, wherein the tested substance is a peptide, peptide mimetic agent, antibody, antibody fragment or antibody derivative.

14. (twice amended) A method for identifying an agent which induces apoptosis, comprising incubating a putative agent with a glycoprotein according to claim 2 and determining if it binds specifically, wherein said putative agent is not the monoclonal antibody SC-1.

15. (twice amended) A method for identifying an antitumor agent, comprising incubating a putative agent with a glycoprotein according to claim 2 and determining if it binds specifically, wherein said putative agent is not the monoclonal antibody SC-1.

16. (twice amended) A method for identifying an agent for tumor diagnosis, comprising incubating a putative agent with a glycoprotein according to claim 2 and determining if it binds specifically, wherein said putative agent is not the monoclonal antibody SC-1.

C³
Cont

17. (twice amended) A method for preparation of a pharmaceutical composition that induces apoptosis, comprising identifying an agent which binds specifically to a glycoprotein according to claim 2, and includes apoptosis, and combining it with a pharmaceutically acceptable adjuvant, additive and/or vehicle.

18. (twice amended) A process for the preparation of an anti-tumor agent, comprising identifying an agent which binds specifically to a glycoprotein according to claim 2 and combining it with a pharmaceutically acceptable adjuvant, additive or vehicle.

19. (twice amended) A process for combatting tumors, comprising administering to a patient in need thereof an anti-tumor-effective amount of a substance that binds specifically to a glycoprotein according to claim 2, with the exception of monoclonal antibody SC-1.

20. (twice amended) A process for the diagnosis of a tumor, comprising contacting a sample or a patient with a substance that binds specifically to a glycoprotein according to claim 2, and detecting, localizing and/or quantitating said glycoprotein in the sample or in the patient.

23. (twice amended) A method for inducing an apoptotic process in a cell which does not comprise cleavage of poly (ADP-ribose) - polymerase (PARP), comprising contacting said cell with a substance that specifically binds a glycoprotein according to claim 2.

C⁴

24. (twice amended) A method for inducing cell cycle arrest in a tumor cell, comprising contacting said tumor cell with a substance that binds specifically a glycoprotein according to claim 2.

25. (twice amended) A method for inducing apoptosis in a dormant tumor cell, comprising contacting said tumor cell with a substance that binds specifically to a glycoprotein according to claim 2.

Please add the following new claims 30-37 as follows:

-- 30. The method according to claim 7, wherein the ability to induce apoptosis in tumor cells is tested.

31. The method according to claim 9, wherein the glycoprotein is in the form of a cell extract.

32. The method according to claim 31, wherein the glycoprotein is in the form of a membrane preparation.

C5
33. The method according to claim 9, wherein the glycoprotein is in the form of an intact cell.

34. The method according to claim 33, wherein the cell is from the human adenocarcinoma cell line 23132.

35. A pharmaceutical composition, comprising an agent which binds specifically to a glycoprotein according to claim 2, and a pharmaceutically acceptable carrier, wherein said agent is not monoclonal antibody SC-1.

36. The pharmaceutical composition according to claim 35, which induces apoptosis.

37. The pharmaceutical composition according to claim 35, which is an antitumor agent.